Pharmafile Logo
Pharmafocus logo
Advanced Search

NHE3

Showing 1 posts of 1 posts found.

AZ licences renal disease compound

October 9, 2012
Research and Development, Sales and Marketing Ardelyx, AstraZeneca, NHE3

AstraZeneca has signed an agreement giving it worldwide exclusive rights to California-based Ardelyx’s NHE3 inhibitor programme targeting liver and kidney …

News
The Gateway to Local Adoption Series

Latest content

Pharma sees climate disruption as growing supply-chain risk

September 11, 2026

Manchester NHS-MHRA partnership to test new technologies in real-world care

September 10, 2026

Ondine reports 40% reduction in surgical-site infections in phase 3 trial

September 9, 2026

Northern Ireland to roll out staff well-being training across health service

September 8, 2026

European consortium demonstrates continuous manufacturing platform for pharmaceutical ingredients

September 7, 2026